scholarly journals Gynaecological Malignancies

2010 ◽  
pp. 171-182 ◽  
Author(s):  
M. Morgia ◽  
L. Walsh ◽  
M. Milosevic ◽  
W. Levin ◽  
A. Fyles
Keyword(s):  
Gynaecological Malignancies

The association of gynaecological malignancies with hemorheological parameters during the surgical interventions

2016 ◽  
Vol 76 (10) ◽  
Author(s):  
P Pinidis ◽  
A Liberis ◽  
Z Koukouli ◽  
P Naoumis ◽  
C Bouschanetsis ◽  
...  
Keyword(s):  
Surgical Interventions ◽  
Gynaecological Malignancies

Lipophilic Statins as Anticancer Agents: Molecular Targeted Actions and Proposal in Advanced Gynaecological Malignancies

2015 ◽  
Vol 16 (10) ◽  
pp. 1142-1159 ◽  
Author(s):  
Salvatore Gizzo ◽  
Michela Quaranta ◽  
Giovanni Battista Nardelli ◽  
Marco Noventa
Keyword(s):  
Anticancer Agents ◽  
Gynaecological Malignancies

scholarly journals Hormone Replacement Therapy After Gynaecological Malignancies: a Review Article

2021 ◽  
Vol 81 (05) ◽  
pp. 549-554
Author(s):  
Marina Sourouni ◽  
Ludwig Kiesel
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Current Knowledge ◽  
Hormone Replacement ◽  
Oncological Treatment ◽  
Oncological Safety ◽  
Risks And Benefits ◽  
Gynaecological Malignancy ◽  
Gynaecological Malignancies ◽  
Broad Overview

AbstractRapid advances in oncology have led to an increased survival rate in cancer patients, who live long enough to reach the natural age of menopause or experience the end of gonadal function as a side effect of oncological treatment. Survivors after gynaecological malignancies are a major challenge as these diseases are hormone-dependent and hormone replacement therapy (HRT) possibly increases the risk of recurrence. This article is based on a selective literature search for relevant studies and guidelines regarding HRT after gynaecological malignancies and provides a broad overview of current research. The data for assessing the oncological safety of HRT after gynaecological malignancy are insufficient overall. According to current knowledge, HRT is fundamentally contraindicated after breast and endometrial cancer. After ovarian cancer, HRT can be used after assessment of the risks and benefits, while there is usually no contraindication to HRT after vulvar, vaginal or cervical cancer.

scholarly journals 105 Functional Recovery in Older Women Undergoing Surgery for Gynaecological Malignancies: A Systematic Review and Narrative Synthesis

2020 ◽  
Vol 49 (Supplement_1) ◽  
pp. i34-i36
Author(s):  
F E Martin ◽  
T Kalsi ◽  
J K Dhesi ◽  
J S L Partridge
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Older Women ◽  
Functional Recovery ◽  
Narrative Synthesis ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
Gynaecological Malignancies

Abstract Introduction Older women are increasingly undergoing surgery for gynaecological malignancies. Although survival data is available other outcomes such as functional recovery are less well described. However older people are both more vulnerable to changes in function and often prioritise function over survival. There is limited published research examining function outside of context of sexual or urodynamic function following gynaeoncology surgery but a large body or research exists examining health-related quality of life (HrQOL) both as a pre-operative risk factor for survival and as a post-treatment outcome measure in its own right. HRQOL tools may report on physical function as a subcomponent within composite tools. This systematic review and narrative synthesis describes functional recovery after gynae-oncology surgery with respect to baseline characteristics which - if identified – could enable pre- or post-operative risk reduction. Methods Systematic search of MEDLINE and EMBASE databases and Cochrane Library between 1974-2018. Two reviewers independently reviewed abstracts/papers for inclusion against the following criteria:Mean/median age >60Gynaeoncological treatment includes surgery (RCTs, observational or mixed methods studies).Any measure of functional ability as defined by WHO ICF classification section D1–D7 inclusive, D855, D860-79 and D9 using validated tool.Minimum pre-operative and one post-operative measure. Results analysed and presented using narrative synthesis. Results Sixteen studies identified (7 Endometrial, 2 Ovarian, 2 Vulval, 6 mixed cancer types). 1/16 used a standalone functional assessment tool, 15/16 used Health-Related Quality of Life tools (EORTC QLQ C30 (10), FACT-G (3), SF-36 (3)) comprising items describing function. More studies showed full recovery to baseline (n=11) than incomplete recovery (n=5 including 2 reporting age as a negative association). Recovery was more likely and occurred faster in minimally-invasive surgery. 1 study demonstrated failure to recover baseline functional independence by 12 months.

Computed Tomography in Gynaecological Malignancies

Radiology ◽  
1984 ◽  
Vol 151 (2) ◽  
pp. 438-438
Author(s):  
M. J. McLoughlin
Keyword(s):  
Computed Tomography ◽  
Gynaecological Malignancies

scholarly journals Retrospective analysis of acute and late gastrointestinal and hematological toxicities with extended field radiation in gynaecological malignancies: A single institution data

2016 ◽  
Author(s):  
Chaitanya Medichelme ◽  
Shagun Juneja ◽  
Anirudh Punnakal ◽  
Charu Garg ◽  
Indu Bansal ◽  
...  
Keyword(s):  
Volumetric Modulated Arc Therapy ◽  
Late Toxicity ◽  
Concurrent Chemotherapy ◽  
Planning System ◽  
Hematological Toxicity ◽  
Ct Simulation ◽  
Field Radiation ◽  
Extended Field ◽  
Gynaecological Malignancies ◽  
Grade 3

Purpose: The aim of this study is to report a preliminary analysis of our clinical experience with extended field pelvic (conformal) radiation, with or without concurrent chemotherapy, in gynaecological malignancies. Materials and Methods: 27 women with gynaecological malignancies (17 with Carcinoma Cervix and 10 with Carcinoma Endometrium) were treated between November 2009 and October 2015 with Extended Field abdomino-pelvic radiation. All patients were treated with conformal radiation (Intensity Modulated Radiotherpy or Volumetric Modulated Arc Therapy). All patients underwent CT Simulation followed by target and OAR delineation as per RTOG guidelines. Dose prescriped was 45-50 Gy in 1.8 Gy per fraction and boost to gross node upto 54-56 Gy. Planning was done on Eclipse Planning system, and treatment was delivered on 6 MV linac. Concurrent chemotherapy was given when indicated. All toxicities were scored according to Common Terminology Criteria for Adverse Events (CTCAE v 4.03). Dosimetric parameters were correlated with toxicities. Results: Median follow up was 9.5 months (Range 0-52 months). 14 (51.8%) patients developed Grade 1 and 2 acute hematological toxicity and 1 (0.04%) developed Grade 3 toxicity. 10 (37%) patients developed Grade 1 and 2 acute gastrointestinal toxicity and 1 (0.04%) developed grade 4 toxicity. 3 (11.12%) patients had late toxicity in the form of prolonged leucopenia, SAIO, and Irritable Bowel Syndrome. 1 patient did not complete her treatment due to persistent leucopenia (Grade 3). Conclusion: Extended field Radiation in Gynaecological malignancies is a reasonably well tolerated procedure when treated with IMRT or VMAT, with acceptable toxicity profile.

scholarly journals Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO

2004 ◽  
Vol 34 (8) ◽  
pp. 743-744 ◽  
Author(s):  
A Perillo ◽  
G Ferrandina ◽  
L Pierelli ◽  
S Rutella ◽  
S Mancuso ◽  
...  
Keyword(s):  
Gynaecological Malignancies

scholarly journals Gynaecological malignancies from palliative care perspective

2011 ◽  
Vol 17 (4) ◽  
pp. 45 ◽  
Author(s):  
Kamlesh Mishra
Keyword(s):  
Palliative Care ◽  
Gynaecological Malignancies
Sign in / Sign up

Export Citation Format

Share Document